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The essential osteoblast-related transcription factor Runx2 and the female steroid hormone estrogen are known
to play pivotal roles in bone homeostasis; however, the functional interaction between Runx2- and estrogen-
mediated signaling in skeletal tissues is minimally understood. Here we provide evidence that aromatase (CYP19),
a rate-limiting enzyme responsible for estrogen biosynthesis in mammals, is transcriptionally regulated by Runx2.
Consistent with the presence of multiple Runx2 binding sites, the binding of Runx2 to the aromatase promoter was
demonstrated in vitro and confirmed in vivo by chromatin immunoprecipitation assays. The bone-specific aromatase
promoter is activated by Runx2, and endogenous aromatase gene expression is upregulated by Runx2 overexpres-
sion, establishing the aromatase gene as a target of Runx2. The biological significance of the Runx2 transcriptional
control of the aromatase gene is reflected by the enhanced estrogen biosynthesis in response to Runx2 in cultured
cells. Reduced in vivo expression of skeletal aromatase gene and low bone mineral density are evident in Runx2
mutant mice. Collectively, these findings uncover a novel link between Runx2-mediated osteoblastogenic processes
and the osteoblast-mediated biosynthesis of estrogen as an osteoprotective steroid hormone.
Runx2 is an essential transcription factor in bone formation
during embryogenesis (40). The ablation or C-terminal trun-
cation of Runx2 prevents bone formation (3, 16), and a het-
erozygous mutation of Runx2 results in cleidocranial dysplasia
in both mice and humans (15, 17). Mechanistically, Runx2
positively regulates osteoblast proliferation through epigenetic
control (30) and differentiation through the upregulation of
bone-related target gene expression (1, 5). Moreover, Runx2
accelerates chondrocyte differentiation in response to the up-
regulation of Runx2 target genes, which include the Indian
hedgehog (Ihh) and type X collagen (Col10A1) genes (32, 55).
The control of chondrogenesis by Runx2 is further confirmed
by the chondrocyte-specific overexpression of a dominant neg-
ative form of Runx2 in transgenic mice (42, 50). Runx2 also
plays an important role in estrogen deficiency-mediated bone
resorption in adult mice (20). Together, these studies establish
Runx2 as a master regulator of bone formation through the
modulation of the activity of a cohort of target genes.
Estrogen is essential for the maintenance of bone health in
both men and women (41). Estrogen deficiency is associated
with increased bone turnover, resulting in reduced bone min-
eral density (BMD) and increased fracture risk. One of the key
roles of estrogen is to modulate osteoclast survival, revealed by
a loss of osteoclast apoptosis in osteoclast-specific estrogen
receptor alpha (ER-) conditional knockout mice (24). In ad-
dition, estrogen inhibits osteoclast formation through the up-
regulation of osteoprotegerin production (53). Therefore, the
mutation or ablation of genes in the pathway related to estro-
gen synthesis causes a disruption of bone homeostasis. For
example, a mutation of the ER- gene in males can lead to
osteopenia and even osteoporosis (11). Mutations of the aro-
matase gene result in unfused epiphyses and osteoporosis in
males, and aromatase-deficient mice exhibit osteoporosis (11).
The human aromatase gene (CYP19; P450arom) is com-
prised of a 30-kb coding region containing nine exons and a
93-kb regulatory region containing 10 untranslated exons I (2,
38). The gene is expressed in many tissues, including the ova-
ries (8), muscle, skin, adipose tissue (18, 19, 54), placenta (28),
and bone (25, 26, 33, 34, 43). The unusually large regulatory
region contains 10 tissue-specific promoters that are alterna-
tively used in various cell types (2, 38). Each promoter is
regulated by a distinct set of regulatory sequences in the DNA
and transcription factors that bind to these specific sequences.
The promoters specific for the ovary tissues (promoter II),
bone tissues (I.4 and I.6), brain (I.f), endothelial cells (I.7),
fetal tissues (I.5), and placenta (2a; I.1) are localized in tandem
at 0, 73, 1, 33, 36, 43, 78, and 93 kb upstream of the ATG
translational start site in exon II. Previous findings suggested
that the local expression of aromatase may regulate estrogen
production and perhaps affect local bone homeostasis. The
majority of aromatase transcripts in bone tissues contain exon
1.4 and exon 1.6 in the 5 untranslated region (5-UTR) (35,
52); however, there is little information on the regulation of
the aromatase gene in bone.
* Corresponding author. Mailing address: Department of Biochem-
istry and Cell Biology, School of Medicine, Kyungpook National Uni-
versity, 101 Dongin-Dong, Jung-Gu, Daegu 700-422, Republic of Ko-
rea. Phone: 82-53-420-4823. Fax: 82-53-422-1466. E-mail: jechoi@knu
.ac.kr.
 Published ahead of print on 15 March 2010.
2365
Recent studies revealed that Runx2 is involved in the estro-
gen pathway through interactions with ER- (21) or as a down-
stream target gene of estrogen or SERM (45, 48). Further-
more, Runx2 was recently shown to control the expression of
GPR30/GPER, which represents a nongenomic cell surface
receptor for estrogen that is essential for osteoblast prolifera-
tion in cell culture (47). Although accumulating evidence im-
plicates a functional association of Runx2 with estrogen sig-
naling (13, 21, 45, 48), Runx2 has not been directly shown to
control estrogen biosynthesis. Aromatase is a rate-limiting en-
zyme in the conversion of testosterone into estrogen and plays
a pivotal role in estrogen synthesis. Hence, in the present
study, we addressed a possible functional link between aro-
matase and Runx2. We found that Runx2 increases aromatase
gene expression, establishing the functional involvement of
Runx2 in the estrogen biosynthesis pathway.
MATERIALS AND METHODS
Cell culture. Human mesenchymal stem cells (hMSC) and media (mesenchy-
mal stem cell growth medium [MSCGM]) were purchased from Lonza (Walk-
ersville, MD). HOS and MG63 cells (human osteosarcoma cell lines), HCS-2/8
cells (human chondrocyte cell line), primary cultured human chondrocytes, and
HeLa cells were cultured and maintained in Dulbecco’s modified Eagle’s me-
dium (DMEM; Gibco, Grand Island, NY) supplemented with 10% fetal bovine
serum (FBS; Gibco), 100 U/ml penicillin, and 100 g/ml streptomycin at 37°C in
a humidified atmosphere containing 5% CO2. CHO cells were cultured in
-modified minimum essential medium supplemented with 10% FBS.
Total RNA, mRNA isolation, and RT-PCR analysis. Total RNA was isolated
from cells by using TRIzol reagent (Invitrogen, Carlsbad, CA) and mRNA was
extracted by using an Oligotex mRNA Midi kit (Qiagen, Hilden, Germany)
according to the manufacturers’ instructions. Reverse transcriptase PCR (RT-
PCR) was performed by using Superscript II RT (Invitrogen) according to the
manufacturer’s instructions. The PCR conditions were 94°C for 10 min, followed
by 35 cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 30 s, with a final
extension step at 72°C for 10 min. Primers used for aromatase transcripts I.4 and
I.6 in bone cells were as follows: exon I.4-F (5-GAC CAA CTG GAG CCT
GAC AG-3), exon I.6-F (5-CAC AGC AGA ACC AGC ACA TCA-3), and
exon 2-R (5-GTG CCC TCA TAA TTC CAC AC-3).
Real-time RT-PCR analysis. Real-time PCR was performed for the relative
quantification of aromatase mRNA levels by using SYBR green PCR master mix
(Applied Biosystems, Foster City, CA) and primers designed by using Primer-
Express software (Applied Biosystems). Total RNA (3 g) was reverse tran-
scribed, and 200 ng of cDNA was used as a template for each PCR. SYBR green
PCR master mix (25 l) and 1 l of specific primers (10 pmol) were combined
with template and water in a total volume of 50 l. A negative control with no
template was also included in each assay. PCR was performed at 95°C for 10 min,
followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Primers for the human
aromatase gene were 5-TCA CTG GCC TTT TTC TCT TGG T-3 and 5-GGG
TCC AAT TCC CAT GCA-3, primers for the mouse aromatase gene were
5-AAA TGC TGA ACC CCA TGC AG-3 and 5-AAT CAG GAG AAG GAG
GCC CAT-3, and primers for the GAPDH (glyceraldehyde-3-phosphate dehy-
drogenase) gene were 5-TGG GCT ACA CTG AGC ACC AG-3 and 5-GGG
TGT CGC TGT TGA AGT CA-3.
Construction of Luc reporter genes. To clone the human aromatase gene I.4
and I.6 promoters, PCR products (0.74 kb/0.14 kb and 1.0 kb, respectively) were
amplified from human blood genomic DNA by using the following primers.
Forward primers for the 0.74-kb and 0.14-kb I.4 promoters were KpnI-P1 (5-
ACC GGT ACC CTC TGG TCA GAT ATT TTG ATC ATG-3) and KpnI-P2
(5-ACC GGT ACC TTA TTG GAA AGA TGC ACA TTG AAT-3), respec-
tively, used with common reverse primer XhoI-P2 (5-ATT GCT CGA GTT
TCC CAA TCT AGT TTC TAG ATT T-3). Primers for the I.6 promoter were
KpnI-P1.6F (5-AGG TAC CAA CAG GTT TTT TAA AAG TGC TTG C-3)
and XhoI-P1.6R (5-ATT GCT CGA GTA GGT AGT CTG TAG CTG AAG-
3). The PCR products were subcloned into the TA cloning vector (Invitrogen)
and subsequently inserted into the pGL3 Luc reporter vector (Promega, Madi-
son, WI). Luciferase (Luc) reporter vectors containing promoters I.4 and I.6
were named pI.4-741-Luc/pI.4-137-Luc and pI.6-1023-Luc, respectively.
We performed site-directed mutagenesis of the Runx2 binding site (RBS) in
the pI.4-741-Luc and pI.6-1023-Luc vectors by using the QuikChange XL site-
directed mutagenesis kit (Stratagene, La Jolla, CA). Primers for the site-directed
mutagenesis of pI.4-741-Luc were 5-AAA TAT GTa cTT CAT GCT GGA ATG
CTG GAC ATA gtA CAT TAT T-3 and 5-AAT AAT GTa cTA TGT CCA
GCA TTC CAG CAT GAA gtA CAT ATT T-3 (lowercase indicates mutation
sites in the Runx2 binding site). Primers used for the site-directed mutagenesis
of pI.6-1023-Luc were 5-TTA AAA AAA AAA CAA gtA CAA AAC TGC
TCA ACA T-3 and 5-ATG TTG AGC AGT TTT GTa cTT GTT TTT TTT
TTA A-3. The resulting plasmids, pI.4-741-Rm-Luc and pI.6-1023-Rm-Luc,
contained pI.4-741-Luc with two RBS mutations and pI.6-1023-Luc with one
RBS mutation, respectively. The DNA sequences of all cloned constructs were
confirmed by sequencing.
Cell transfection and Luc reporter gene assay. HeLa and CHO cells in six-well
plates were plated at a density of 4  105 cells/well for transfection experiments.
Cells were transfected with a total of 2 g DNA, including 0.8 g of the
aromatase promoter I.4 gene-Luc reporter construct, 0.2 g pSV--galactosi-
dase, and various amounts of pcDNA3.1 and pcDNA3.1-Runx2 plasmids by
using Lipofectamine 2000 (Invitrogen), and were grown for 16 h. The ER-
expression vector (kindly provided by K. O. Han, Kwandong University, Seoul,
South Korea) was cotransfected with the reporter vector containing six copies of
the RBS into CHO cells. pSV--galactosidase plasmids were included as an
internal control for transfection efficiency. All transfections were performed in
triplicate. At 16 h or 24 h after transfection, cells were washed twice with
phosphate-buffered saline (PBS) (pH 7.4) and harvested with lysis buffer (Pro-
mega). Luc activity was determined with the luciferase assay system (Promega)
and measured with a luminometer (AutoLumat LB953; EG & Gberthold, Ger-
many). The ratio of Luc activity relative to -galactosidase activity and the total
protein content in the lysates were used to normalize for transfection efficiency.
Each transfection was conducted in triplicate, and the results are presented as
means  standard deviations (SD).
EMSA. The human osteosarcoma cell line HOS was maintained in DMEM
(Gibco) containing 10% FBS. The methods used for nuclear extraction prepa-
ration and electrophoretic mobility shift analysis (EMSA) were described previ-
ously (14). Sequences of the wild-type and mutant oligonucleotides used are as
follows: 5-GGA AAT ATG TGG TTC ATG-3 and 5-CAG CAT GAA CCA
CAT ATT-3, respectively, for 1.4-Runx2-1; 5-GGA CAT ACC ACA TTA TTG
GAA AGA-3 and 5-GCA TCT TTC CAA TAA TGT GGT ATG-3, respec-
tively, for 1.4-Runx2-2; 5-GGA AAT ATG Tac TT C ATG-3 and 5-CAG CAT
GAA gtA CAT ATT-3, respectively, for 1.4-Runx2-1-mut; and 5-GGA CAT
Agt ACA T TA TTG GAA AGA-3 and 5-GCA TCT TTC CAA TAA TGT acT
ATG-3, respectively, for 1.4-Runx2-2-mut. Probes were end labeled with
[-32P]dCTP by use of the Megaprime DNA labeling system (GE Healthcare UK
Ltd., Buckinghamshire, United Kingdom). Nuclear extract (15 g) was incubated
with 1 gel shift binding buffer containing 15 mM Tris (pH 7.5), 1 mM MgCl2,
0.5 mM EDTA, 0.5 mM dithiothreitol, 50 mM NaCl, 10% glycerol, and 1 g
poly(dI-dC) for 30 min at 4°C. Competition was performed with a 100-fold
molar excess of unlabeled DNA probe. Reaction mixtures were separated on
6% nondenaturing polyacrylamide gels in 0.5 Tris-borate-EDTA (TBE)
buffer (50 mM Tris-HCl [pH 8.5], 50 mM borate, and 1 mM EDTA). For
supershift assays, the nuclear extract was pretreated with mouse monoclonal
Runx2 antiserum (30) at room temperature for 30 min before the addition of
the labeled probe.
ChIP analysis. Chromatin immunoprecipitation (ChIP) assays were per-
formed with a human osteosarcoma cell line, HOS. HOS cells (2  106 cells)
were exposed to 1% formaldehyde in DMEM for 10 min at 37°C. Glycine was
added to 0.125 M, and the cultures were incubated for 2 min. The cells were
collected in cold PBS, pelleted by centrifugation, and incubated for 10 min on ice
in 0.3 ml SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl [pH 8.1]).
Lysed samples were sonicated at 30% power with a Sonic Dismembrator model
500 sonicator (Fisher Scientific Inc., Pittsburgh, PA) for 12 10-s pulses at 4°C.
The reaction mixtures were centrifuged for 10 min at 4°C to remove debris and
stored at 80°C. A 200-l aliquot was diluted with 1.8 ml of buffer (0.01% SDS,
1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl [pH 8.1], 167 mM NaCl)
and precleared with 80 l salmon sperm DNA-protein A-Sepharose for 2 h at
4°C. After the removal of the Sepharose beads by centrifugation, 2 l anti-
Runx2, 2 l anti-hemagglutinin (HA) (Covance Inc., CA) (unrelated antibody),
5 g normal mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA), or no
antibody was added to the supernatant, and the reaction mixture was incubated
overnight at 4°C. Antibody-protein-DNA complexes were isolated by incubation
with 45 l of blocked protein A-Sepharose for 2 h at 4°C. After extensive
washing, bound DNA fragments were eluted and analyzed by PCR. Cycling
parameters were 1 cycle of 95°C for 10 min and 28 cycles of 95°C for 30 s, 56°C
for 30 s, and 72°C for 30 s. The primers used for the amplification of the
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aromatase promoter were 5-CAA AGT GCT TGT CCC CTC A-3 and 5-TGT
CGG TCA TTC AAT GTG CA-3. The negative-control primers used for the
amplification of a 3.7-kb region of aromatase promoter I.4 were 5-TAA CAA
CAG CAG AAG CAG CA-3 and 5-GCT GAG CAG AGA ACA AGC A-3.
Amplified products were electrophoresed through a 2% agarose gel and visual-
ized by ethidium bromide staining.
Adenovirus infection. Adenovirus particles expressing Runx2 were generated
by using the adEasy Adenovector system (Qbiogene, Carlsbad, CA) (9, 31). HOS
and MG63 cells in six-well plates were plated at a density of 1.2  105 to 2  105
cells/well. One day after seeding, cells were infected with Runx2-expressing
adenovirus in DMEM with 1% FBS for 4 h and then cultured for 24, 36, and 60 h
in DMEM with 10% FBS.
Hormone assays. The concentration of estrogen and progesterone in the
culture medium was measured by a combined method between an enzyme
immunoassay sandwich and a final fluorescent detection called an enzyme-linked
fluorescent assay (ELFA). Concentrations of 17--estradiol (-E2) and proges-
terone in the culture medium (0.2 ml) were measured with a Vidas instrument
(bioMe´rieux Inc., Durham, NC) using Vidas estradiol II and a Vidas progester-
one kit (bioMe´rieux Inc.) according to the manufacturer’s protocols.
Western blot analysis. Whole cells were lysed in radioimmunoprecipitation
assay (RIPA) buffer (10 mM Tris-HCl [pH 7.4], 0.15 M NaCl, 0.5% SDS, 1%
NP-40, 1% Na-deoxycholate, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride
[PMSF], 1 g/ml pepstatin, and 1 g/ml leupeptin), and the protein concentra-
tion was determined by using the Bradford protein assay kit (Bio-Rad, CA).
Proteins were separated on 10% SDS-polyacrylamide gels and transferred onto
polyvinylidene difluoride (PVDF) membranes. Blots were blocked with 5% skim-
milk powder in Tris-buffered saline (TBS) (20 mM Tris-HCl, 137 mM NaCl [pH
7.6]) containing 0.1% Tween 20 (TBS-T buffer) for 1 h at room temperature.
Western blot analyses were performed with anti-Runx2 (30), antiaromatase
(Serotec, Oxford, United Kingdom, or Acris Antibodies GmbH, Hiddenhausen,
Germany), anti-MMP13 (Calbiochem, La Jolla, CA), and anti--tubulin (Santa
Cruz Biotechnology) antibodies. Primary antibodies were added in TBS-T buffer
at a 1:1,000 dilution and incubated for 90 min at room temperature prior to
incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies
(1:5,000 dilution; Santa Cruz Biotechnology) for 1 h at room temperature.
Proteins were detected by using an enhanced chemiluminescence detection sys-
tem (GE Healthcare).
Animals and genotyping. Animal care and experiments were carried out in
accordance with the Institutional Animal Care and Use Committees of Kyung-
pook National University. Animals were maintained on a 12-h light–12-h dark-
ness cycle at 22°C to 25°C under specific-pathogen-free (SPF) conditions and fed
with standard rodent chow and water ad libitum. Genotyping of Runx2 null and
Runx2	C mice was performed as previously described (10). For sex determina-
tions, genomic DNA from pups was obtained and analyzed for the presence of
Sry by PCR as previously described (10).
Immunohistochemical analysis. A Vectastain Elite-ABC kit (Vector Labora-
tories, Inc., CA) was used for immunohistochemistry. The lower limbs of em-
bryonic day 17.5 (E17.5) embryos were fixed in 4% paraformaldehyde in 0.1 M
PB (sodium phosphate buffer) for 16 to 42 h at 4°C. Specimens were dehydrated,
embedded in paraffin, and cut into sections of a 5-m thickness. Sections were
deparaffinized, quenched in 1% H2O2 in methanol, washed in PBS, and incu-
bated for 2 h at room temperature with diluted normal goat blocking serum prior
to overnight incubation at 4°C with anti-aromatase primary antibody (diluted
1:200 in PBS). The slides were washed three times for 10 min with PBS, incubated
for 1 h with Vectastain Elite ABC reagent, and washed three times with PBS. Slides
were developed by using a Dako (Glostrup, Denmark) Liquid DAB
 substrate-
chromogen system, with counterstaining with 1% methyl green in double-distilled
water (ddH2O). In control experiments, the antibody was replaced with normal
rabbit IgG. The signal was captured by using a Nikon light microscope.
Isolation of bone marrow stromal cells. Bone marrow stromal cells (BMSC)
were collected from 8-week-old female wild-type and Runx2
/ mice (10). The
mice were sacrificed, and femora and tibiae were isolated. After the dissection of
attached muscle and connective tissue from the bones, metaphyses of femurs and
tibias were cut aseptically, and the diaphysis cavities were flushed with DMEM
(Gibco) supplemented with 20% FBS (Gibco), 100 U/ml penicillin, and 100
g/ml streptomycin using a 26-gauge needle. After 24 h, nonadherent cells and
debris were removed, and the adherent cells were cultured continuously. BMSC
at passage 3 were used for experiments.
BMSC were plated in six-well plates at a density of 1  105 cells in DMEM
supplemented with 20% FBS. One day after seeding, the culture medium was
used for measurements of -E2 and progesterone as described above.
Micro-computed tomography (micro-CT) analysis. To determine three-di-
mensional bone structure in vivo, we performed histomorphometric analysis with
the eXplore Locus SP scanner (GE Healthcare) at an 8-m resolution. All
morphometric parameters were determined by using eXplore MicroView, ver-
sion 2.2 (GE Healthcare). In the femora, scanning regions were confined to the
distal metaphysis extending proximally 1.7 mm from the proximal tip of the
primary spongiosa.
Establishment of a stable Runx2-expressing cell line. HeLa cells were trans-
fected with the pcDNA3.1 or pcDNA3.1-Runx2 expression vector by using
LipofectAMINE 2000 reagent (Invitrogen), and transfected cells were selected
and maintained in culture medium containing G418 (0.4 mg/ml). Selected cells
were plated in a six-well plate at a density of 1  105 cells in DMEM with 10%
FBS. The culture medium was used for measurements of -E2 and progesterone
at 16 h or 4 days after seeding.
Statistical analysis. Data were expressed as the means SD from three or more
independent experiments. Differences between two groups were evaluated by using
a Student’s t test. Results were considered significant at a P value of 0.05.
RESULTS
Runx2 increases aromatase gene expression. Tissue-specific
aromatase gene expression is determined by alternative pro-
moter usage. Among the multiple aromatase gene promoters,
I.4 and I.6 have been shown to be bone specific (2, 7, 35, 36,
52). To confirm aromatase promoter utilization in bone cells,
we performed RT-PCR analysis of RNA from various bone
cell lines. The amplified PCR products were portions of the
5-UTR derived from promoter I.4 or promoter I.6, and both
transcripts were successfully detected based on their expected
size (Fig. 1A). Identities of the PCR products were confirmed
by sequencing (Fig. 1B). Both promoters I.4 and I.6 were active
in human primary mesenchymal stem cells, human chondro-
cytic HCS-2/8 cells, and the human osteoblast cell lines HOS
and MG63 (Fig. 1A). Interestingly, we also identified novel
5-UTR sequences of aromatase mRNA containing exon 1.4
and exon 1.f joined to the exon 2 open reading frame in
chondrocytes (Fig. 1B and 2A). The function of these novel
5-UTR variants in chondrocytes remains to be established.
Our results confirm that aromatase is expressed in bone cells,
including chondrocytes, osteoblasts, and mesenchymal stem
cells, as previously reported (2, 7, 33, 35, 36, 52).
The promoter sequences for the bone-specific I.4 and I.6
aromatase gene transcripts were examined by using the TF
search program (http://www.cbrc.jp/research/db/TFSEARCH
.html). Putative Runx2 binding sites were identified in both the
I.4 and I.6 promoters (Fig. 2A and B). To investigate the
aromatase gene as a downstream target gene of Runx2, we
focused on the I.4 promoter because this promoter showed
strong activity in mesenchymal stem cells, chondrocytes, and
osteoblasts (Fig. 1A). First, we determined whether the puta-
tive Runx2 binding sites in the I.4 aromatase promoter exhib-
ited Runx2 binding activity. Electrophoretic mobility shift anal-
ysis (EMSA) showed Runx2 DNA binding activity for site 1
(TGTGGT) and site 2 (ACCACA) (Fig. 3A). The specificity of
Runx2 binding was revealed by supershifting mediated by anti-
Runx2 antibody. Furthermore, Runx2 binding activity on the
endogenous aromatase gene promoter was confirmed by ChIP
analysis (Fig. 3B). There were no positive signals in various
controls, including the PCR control (H2O), immunoprecipita-
tion controls, and a 3.7-kb upstream unrelated primer control
(Fig. 3B). In transient transfection assays, the forced expres-
sion of Runx2 increased pI.4-741-Luc activity in HeLa cells
(Fig. 3C). The enhancing effect of Runx2 on pI.4-741-Luc
activity was also observed for CHO cells. To determine the
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contribution of Runx2 binding sites to pI.4-741-Luc activity,
vectors pI.4-137-Luc and pI.4-741-Rm-Luc, containing deleted
or mutated Runx2 binding sites, respectively, were constructed.
As expected, Runx2 increased pI.4-741-Luc activity, but the
mutant Luc reporters with deleted or mutated Runx2 binding
sites exhibited basal levels of activity (Fig. 3D). We also deter-
mined the effect of Runx2 on the activity of promoter I.6.
Runx2 increased pI.6-1023-Luc activity, and site-directed mu-
tagenesis in the single Runx2 binding site of the pI.6-1023-Luc
reporter abrogated this effect (data not shown). Taken to-
gether, these results indicate that Runx2 is a positive regulator
of bone-specific aromatase gene expression.
Runx2-mediated upregulation of aromatase gene expression
increases estrogen production. Our previous findings indicated
that Runx2 is a positive regulator of aromatase gene expression
(Fig. 3). We therefore investigated whether the Runx2-medi-
ated upregulation of aromatase results in increased estrogen
production. To test this hypothesis, the bone cell lines HOS
and MG63 were infected with adenovirus-producing Runx2
(Fig. 4). The forced expression of Runx2 increased estrogen
production in HOS cells (Fig. 4A) and MG63 cells (Fig. 4B);
however, the progesterone concentration in the adenovirus-
transduced culture medium was not changed (data not shown).
These results were recapitulated in Runx2-negative HeLa cells
FIG. 1. Aromatase gene expression and promoter activity in bone cells. (A) Expression of exons I.4 and I.6 in primary cultured human
mesenchymal stem cells (hMSCs), the human chondrocyte HCS-2/8 cell line, primary cultured human chondrocytes (chondrocyte), and human
osteosarcoma HOS cells and MG63 cells. RT-PCR was performed by using specific primers derived from the sequence of the coding region from
exon I.4 or exon I.6 to exon II of the human aromatase gene. The expected PCR products (220 bp and 240 bp) were identified by 2% agarose gel
electrophoresis. The top and bottom arrows indicate exon I.6 and exon I.4, respectively. The 1-kb bands seen in chondrocytes and HOS cells are
contaminating genomic DNA (stars). (B) Sequences of transcripts for exons I.4 and 1.f linked to exon II. A novel transcript of the aromatase gene
5-UTR corresponding to exons I.4 and I.f linked to exon II was observed for the human chondrocyte HCS-2/8 cell line (arrowhead in panel A).
Boxes indicate exon-intron junctions, and the ATG (italic type) in each transcript indicates the translation start site. M, 1-kb molecular size ladder.
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only after making stably expressing Runx2. HeLa cells express-
ing Runx2 showed a strong correlation between aromatase
mRNA and protein and estrogen production (data not shown).
Interestingly, bone-type aromatase promoter I.4 and I.6 tran-
scripts were not detected in HeLa cells (data not shown),
suggesting that another promoter(s) may be involved in
Runx2-mediated aromatase gene expression and the upregu-
lation of estrogen production in Runx2-expressing HeLa cells.
Runx2-expressing HeLa cells showed no morphological change
(data not shown). These results suggest that the Runx2-medi-
ated upregulation of aromatase gene expression increases es-
trogen production.
Aromatase gene expression is downregulated in Runx2 mu-
tant mice. Increased estrogen production in response to
Runx2-mediated aromatase gene expression in vitro is consis-
tent with the notion that Runx2 controls steroidogenesis. We
further investigated the relationship between Runx2, aro-
matase, and estrogen biosynthesis in vivo. Our strategy was to
determine whether a downregulation of Runx2 decreases aro-
matase gene expression and estrogen production in intact an-
imals by measuring aromatase expression and estrogen con-
centrations in Runx2 C-terminally truncated Runx2	C/	C mice
and bone marrow-derived stromal cells (BMSC) of Runx2 het-
erozygous mice, respectively. Western blot analysis showed
decreased levels of expression of aromatase in total proteins
isolated from vertebrae and ribs of embryonic day 17.5 (E17.5)
embryos of Runx2	C/	C mice (Fig. 5A). This decrease was
comparable to the reduction in expression of MMP13, a well-
FIG. 2. Runx2 binding sites in the aromatase promoter. (A) Promoter and coding exons of the aromatase gene. Promoter I.4 and promoter I.6
are indicated by arrows. (B) Sequences of promoter I.4 and Runx2 binding sites. Runx2 binding sites are indicated, from distal (site 1, Runx2-1)
to proximal (site 2, Runx2-2). Exon sequences of the promoter I.4-derived transcript are indicated by capital letters.
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known target of Runx2 (Fig. 5A) (9). A decreased level of
expression of aromatase in the periosteum of Runx2	C/	C mice
by immunohistochemical staining (Fig. 5B) and in the vertebra
of E17.5 embryos of Runx2 knockout mice by Western blot
analysis (data not shown) was also observed. To confirm aro-
matase gene expression in skeletal tissues, we isolated skeletal
tissues separately from 19 E17.5 embryos. Consistent with the
immunohistochemical results, total aromatase mRNA expression
was significantly decreased in the limbs of E17.5 Runx2-null em-
bryos (Fig. 5C). Aromatase gene expression levels were similar
for male and female embryos from each group, based on sex
identification by PCR analysis of the Sry gene (data not shown).
Runx2 is also expressed in BMSC. To explore estrogen pro-
duction in BMSC from Runx2 heterozygotes, the amount of
estrogen and progesterone in culture medium was determined
after 1 day of culture. The level of estrogen production was
decreased in Runx2 heterozygous BMSC without a change in
progesterone production (Fig. 6A), consistent with the results
for the forced expression of Runx2 in human osteosarcoma cell
lines (Fig. 4). Taken together, the expression of aromatase
shows a strong correlation with the production of estrogen,
indicating that Runx2 functions as a positive regulator of aro-
matase in Runx2-expressing tissues.
Low bone mass in Runx2 heterozygous mice. Recently, Sjo¨r-
gren et al. reported that osteoblast-specific aromatase gene
expression resulted in high bone mass (39), and those authors
attributed this finding to the upregulation of osteoprotegerin
production in aromatase-transgenic mice. Based on our in vitro
and in vivo results, it seems likely that Runx2 heterozygotes
with reduced aromatase gene expression levels in bone tissue
would have low bone mass. To prove this hypothesis, we de-
termined various bone parameters by micro-CT analysis. Com-
pared with wild-type mice, Runx2 C-terminally truncated het-
erozygotes showed lower values with regard to trabecular bone
FIG. 3. Runx2 binds directly to aromatase promoter I.4. (A) EMSA was conducted with probes containing the two wild-type Runx2 motifs.
32P-labeled wild-type oligonucleotides were incubated with nuclear extracts from HOS cells in the presence of a 100-fold molar excess of unlabeled
specific oligonucleotides or unlabeled mutant oligonucleotides or in the presence of anti-Runx2 antibody (). The bottom arrows indicate the
positions of the major nuclear protein-DNA complexes, and the top arrows indicate Runx2-supershifted complexes. (B) ChIP analysis was
performed with formaldehyde-cross-linked chromatin isolated from HOS cells and antibody against Runx2. PCR amplification was carried out as
described in Materials and Methods for a total of 28 cycles, and amplified fragments were analyzed by 2% agarose gel electrophoresis. (C) HeLa
cells were cotransfected with the promoter I.4 reporter construct and Runx2 expression vector together with a -galactosidase (-Gal) internal
control vector. The results were normalized to the protein concentration and -Gal activity to account for transfection efficiency. (D) Runx2 did
not stimulate Luc activity from a promoter with a mutant Runx2 binding site (RBS) or 0.14-kb aromatase promoter I.4 in CHO cells. Data
represent the means  SD from three independent experiments. Ab, antibody; Comp, competitor; NE, nuclear extract; W, wild-type oligonucle-
otide; M, mutant oligonucleotide; E, RBS (TGTGGT and ACCACA); X, RBS mutation (TGTacT and AgtACA).
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volume, cortical bone thickness, and total bone mineral density
(BMD) (Fig. 6B).
We next determined the role of ER- in the Runx2-mediated
transactivation function on downstream target genes in the pres-
ence or absence of estrogen. As shown in Fig. 7A, ER- inhibited
the Runx2 transactivation function, and this inhibition was en-
hanced in the presence of estrogen. This result suggests a negative
regulatory loop in the Runx2-aromatase-estrogen axis. Our data
indicate that the local activity of aromatase in bone tissue is
important for the maintenance of bone homeostasis and that
Runx2 is an upstream positive regulator for aromatase gene ex-
pression in bone tissues (Fig. 7B).
DISCUSSION
In this study, we demonstrate that Runx2 stimulates aro-
matase gene expression in skeletal tissues. The aromatase gene
was identified as a Runx2 target gene by four independent
criteria. First, Runx2 interacts directly with the aromatase gene
promoter, as confirmed by EMSA and ChIP assays. Second,
FIG. 4. Forced expression of Runx2 increases estrogen production in bone cells. The concentration of estrogen in culture medium was
measured after infection with adenovirus expressing Runx2 in two bone cell lines, HOS and MG63. The forced expression of Runx2 increased
estrogen production in both HOS (A) and MG63 (B) cell lines. Ad, adenovirus. The values represent the means  SD from three experiments.
, P  0.05; , P  0.005.
FIG. 5. Downregulation of aromatase gene expression in the long bone of Runx2	C/	C mice. (A) Expression of aromatase in vertebrae and ribs
from E17.5 wild-type (WT), Runx2
/	C, and Runx2	C/	C mice. Total proteins were isolated from vertebrae and ribs of E17.5 embryos for Western
blotting. A Runx2 downstream target gene, the MMP13 gene, was included as a positive control, and tubulin was used as an internal control. The
values represent means  SD from three mice per group. **, P  0.005. (B) Immunohistochemical staining of tibial sections with antiaromatase
antibody in Runx2
/	C and Runx2	C/	C mice at embryonic day 17. 5. (C) Real-time RT-PCR showed a reduced aromatase mRNA level in limbs
from E17.5 Runx2 heterozygous or null mice (**, P  0.005). The numbers of embryos in each group were 5 wild-type, 11 heterozygote, and 3
homozygote embryos. Data are expressed as means  SD.
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the transient transfection of Runx2 increases aromatase pro-
moter activity. Third, the estrogen production level is elevated
in bone cell lines after the forced expression of Runx2 but is
decreased in BMSC of Runx2 heterozygotes. Fourth, Runx2-
deficient mice exhibited decreased aromatase expression levels
in bone tissues. Together, these results indicate that the aro-
matase gene is a downstream target gene of Runx2 and that
Runx2 functions as a positive regulator for aromatase. We also
demonstrated that mice heterozygous for a defective Runx2
protein lacking its C terminus exhibit a low bone mineral
density by micro-CT analysis compared with wild-type mice.
These results suggest that the local production of estrogen may
contribute to the maintenance of bone homeostasis.
Aromatase catalyzes the conversion of C19 steroids to es-
trogen and is encoded by a single gene (CYP19) in the human
and mouse genomes (4, 37, 38). Mechanisms controlling aro-
matase gene expression are complicated by the existence of
multiple tissue-specific promoters (2). Aromatase exons I.4
and I.6 were previously reported to be expressed in bone cells,
and strong aromatase promoter activity in several bone cells
was observed in this study. Dexamethasone (25), oncostatin M,
forskolin (51, 52), interleukin-1 (IL-1) (23, 34), IL-11, tumor
necrosis factor alpha (TNF-), transforming growth factor 
(TGF-) (6, 36), and 1,25-dihydroxyvitamin D3 (44) are known
upstream regulators of aromatase gene expression. Runx2 is a
master regulator of osteoblast differentiation. Consistent with
its role in the physiological control of osteoblastogenesis,
Runx2 anabolically modulates bone formation and controls
transcriptional signaling pathways that are linked to glucocor-
ticoids and vitamin D3 (27, 29). In this study, we demonstrate
that Runx2 is also a strong positive regulator of aromatase
gene expression in osteoblastic cells. The Runx2-mediated in-
crease in cellular estrogen production through the upregula-
tion of bone-specific aromatase gene expression may contrib-
ute to the maintenance of bone mineral density in conjunction
with endocrine effects. Furthermore, the possibility arises that
the exogenous expression of Runx2 may perhaps contribute to
the control of steroidogenesis during breast cancer tumorigen-
esis and metastasis (31).
Two reports support the linkage of Runx2 with steroid hor-
mone-mediated bone homeostasis; in one report, high doses of
estrogen were administered (12), and in the other report, bone
marrow ablation was performed for animals with reduced lev-
els of Runx2 (49). Those two studies showed that Runx2 het-
erozygotes are less responsive to estrogen and exhibit delayed
healing. The observed results may be due to a compromised
relationship between Runx2 and an estrogen biosynthesis path-
way or a modified regulatory circuit involving Runx2. The
FIG. 6. Estrogen production in BMSC and micro-CT analysis of Runx2 heterozygotes. (A) Primary cultured BMSC were obtained from
8-week-old wild-type (WT) and Runx2
/ mice. Estrogen and progesterone concentrations were measured by ELFA in 1-day-accumulated
medium as described in Materials and Methods. The values represent means  SD from three experiments. **, P  0.005. (B) Five-month-old
Runx2 C-terminally truncated heterozygotes showed decreased trabecular bone volume, cortical bone thickness, and total BMD. BV/TV, bone
volume per tissue volume. Data are means  SD from eight mice per group. *, P  0.05; **, P  0.005.
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precise relationship between estrogen levels and bone pheno-
typic properties in Runx2 heterozygotes requires further con-
firmation. Interestingly, Runx2 dominant negative transgenic
mice show low bone turnover and low bone mass (20). In our
study, Runx2	C/
 C-terminally truncated mice also showed a
low bone mass. High bone turnover mediated by an estrogen
deficiency requires intact Runx2 expression in bone tissues
(20). Moreover, osteoblast-specific aromatase gene expression
in transgenic mice results in high bone mass (39). Together,
these findings suggest that the fidelity of Runx2 function is
important for aromatase-estrogen-mediated bone homeo-
stasis.
While these studies were in progress, it was revealed that
osteoblasts produce endogenous estrogen receptor agonists
(22). Moreover, Teplyuk and colleagues showed that Runx2
controls enzymes (e.g., Cyp11a1) that support the production
of pregnenolone (46) as well as the expression of the non-
genomic receptor for estrogen (Gpr30/Gper), which is neces-
sary for osteoblast proliferation in cell culture (47). Our study
shows that Runx2 increases the expression of aromatase, the
key enzyme for the conversion of androgen to estrogen. To-
gether, these findings strongly suggest that Runx2 expression in
osteoblasts renders these cells competent to produce func-
tional anabolic steroids that stimulate osteoblast function.
More interestingly, the local production of estrogen in bone
may be related to the Runx2-mediated transactivation function
because ER- interacts directly with Runx2 and modulates its
transcriptional function in the presence of estrogen (13). Re-
sults from this and previous studies indicate a Runx2-aro-
matase-estrogen axis that may be controlled by negative- and
positive-feedback mechanisms.
In summary, we conclude from our findings that the gene for
aromatase, the key enzyme for estrogen synthesis from andro-
gen, is a downstream target gene of Runx2 and a component of
a physiological regulatory network between Runx2 and the
estrogen pathway that may contribute to skeletal development
and bone homeostasis.
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